Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received for publication December 19, 2005
- Accepted for publication January 24, 2006
- Published online April 26, 2006.
Copyright & Usage
© 2006 by Society of Nuclear Medicine
Author Information
- Ambros J. Beer 1 , 2 ,
- Roland Haubner 1 ,
- Ingo Wolf 1 ,
- Michael Goebel 3 ,
- Stephan Luderschmidt 4 ,
- Markus Niemeyer 5 ,
- Anca-Ligia Grosu 6 ,
- Maria-Jose Martinez 1 ,
- Hans Jürgen Wester 1 ,
- Wolfgang A. Weber 1 and
- Markus Schwaiger 1
- 1Department of Nuclear Medicine, Technische Universität München, Munich, Germany; 2Department of Radiology, Technische Universität München, Munich, Germany; 3Department of Orthopedic Surgery, Technische Universität München, Munich, Germany; 4Department of Dermatology, Technische Universität München, Munich, Germany; 5Department of Gynecology, Technische Universität München, Munich, Germany; and 6Department of Radiation Therapy, Technische Universität München, Munich, Germany
- For correspondence or reprints contact: Ambros J. Beer, Department of Nuclear Medicine, Technische Universität München, Klinikum rechts der Isar, Ismaninger Strasse 22, 81675 Munich, Germany. E-mail: beer{at}roe.med.tum.de
Statistics from Altmetric.com
Cited By...
Article usage
Jump to section
Related Articles
Cited By...
- 18F-Alfatide II PET/CT for Identification of Breast Cancer: A Preliminary Clinical Study
- PET-Based Human Dosimetry of the Dimeric {alpha}v{beta}3 Integrin Ligand 68Ga-DOTA-E-[c(RGDfK)]2, a Potential Tracer for Imaging Tumor Angiogenesis
- 68Ga-NOTA-PRGD2 PET/CT for Integrin Imaging in Patients with Lung Cancer
- Role of Positron Emission Tomography for the Monitoring of Response to Therapy in Breast Cancer
- Biodistribution and Radiation Dosimetry of the Integrin Marker 18F-RGD-K5 Determined from Whole-Body PET/CT in Monkeys and Humans
- 18F-ML-10, a PET Tracer for Apoptosis: First Human Study
- Monitoring Tumor Response to Antiangiogenic Sunitinib Therapy with 18F-Fluciclatide, an 18F-Labeled αV{beta}3-Integrin and αV{beta}5-Integrin Imaging Agent
- 2-18F-Fluoropropionic Acid as a PET Imaging Agent for Prostate Cancer
- Radiopharmaceuticals in Preclinical and Clinical Development for Monitoring of Therapy with PET
- PET-Based Biodistribution and Radiation Dosimetry of Epidermal Growth Factor Receptor-Selective Tracer 11C-PD153035 in Humans
- Gene expression profiling-based identification of cell-surface targets for developing multimeric ligands in pancreatic cancer
- Phase I Trial of the Positron-Emitting Arg-Gly-Asp (RGD) Peptide Radioligand 18F-AH111585 in Breast Cancer Patients
- Advances in Anatomic, Functional, and Molecular Imaging of Angiogenesis
- Patterns of {alpha}v{beta}3 Expression in Primary and Metastatic Human Breast Cancer as Shown by 18F-Galacto-RGD PET
- Application of PET/CT in the Development of Novel Anticancer Drugs
- Comparison of Integrin {alpha}v 3 Expression and Glucose Metabolism in Primary and Metastatic Lesions in Cancer Patients: A PET Study Using 18F-Galacto-RGD and 18F-FDG
- [18F]Galacto-RGD Positron Emission Tomography for Imaging of {alpha}v{beta}3 Expression on the Neovasculature in Patients with Squamous Cell Carcinoma of the Head and Neck
- microPET of Tumor Integrin {alpha}v{beta}3 Expression Using 18F-Labeled PEGylated Tetrameric RGD Peptide (18F-FPRGD4)
- Nuclear Imaging Probes: from Bench to Bedside
- Future Issues in Highly Conformal Radiotherapy for Head and Neck Cancer